Previous 10 | Next 10 |
2023-05-31 18:37:35 ET Summary Recursion completed one of biotech's biggest ever IPO's in 2020, raising >$500m. The company wants to "decode biology," which strikes me as a little too ambitious. The business model is all about attracting biotech and pharma clients and earni...
2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...
2023-05-29 08:45:00 ET On May 8, Recursion Pharmaceuticals (NASDAQ: RXRX) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Management says that the moves will help the company use...
SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- Altitude Lab announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive hub as part of Recursion’s recently expanded headquarters. The health care incubator will...
2023-05-23 13:13:50 ET Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX ) jumped for the second straight session on Tuesday to double its market cap in less than three weeks amid investor interest in AI-driven drug development. Recursion ( RXRX ), identified as a “c...
2023-05-23 10:08:04 ET Gainers: CohBar ( CWBR ) +157% . Ocean Biomedical ( OCEA ) +79% . Shuttle Pharmaceuticals ( SHPH ) +46% . Icosavax ( ICVX ) +31% . Recursion Pharmaceuticals ( RXRX ) +20% . Losers: NantHealth ( ...
2023-05-22 12:55:14 ET Gainers: Microbot Medical ( MBOT ) +132% . Greenhill & Co ( GHL ) +117% . Hepion Pharmaceuticals ( HEPA ) +64% . Akebia Therapeutics ( AKBA ) +39% . VectivBio Holding ( VECT ) +36% . Atea Phar...
SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion’s ...
2023-05-08 08:28:43 ET Recursion Pharmaceuticals press release ( NASDAQ: RXRX ): Q1 GAAP EPS of -$0.34. Revenue of $12.13M (+127.6% Y/Y). The increase was due to progress made in our Roche-Genentech collaboration. For further details see: Recursion Pharmaceut...
Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological targets Advanced 4 active clinical trials, including an exploratory Phase 2 study of REC-994 in...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,...